CD47/SIRPα axis: bridging innate and adaptive immunity
Myeloid immune cells are frequently present in the tumor environment, and although they can positively contribute to tumor control they often negatively impact anticancer immune responses. One way of inhibiting the positive contributions of myeloid cells is by signaling through the cluster of differ...
Saved in:
Main Authors: | Sjoerd H van der Burg, Anneloes van Duijn, Ferenc A Scheeren |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/7/e004589.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Engineered macrophage nanoparticles enhance microwave ablation efficacy in osteosarcoma via targeting the CD47-SIRPα Axis: A novel Biomimetic immunotherapeutic approach
by: Xiongfa Ji, et al.
Published: (2025-05-01) -
Ubiquitination of CD47 Regulates Innate Anti‐Tumor Immune Response
by: Qian Gou, et al.
Published: (2025-02-01) -
PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47/SHP2/SIRPα/SYK/FcγR signalings in tumor associated macrophages
by: Deyou Kong, et al.
Published: (2025-01-01) -
The Immunotherapeutic Effect of SIRPα-Silenced DCs against Cervical Cancer
by: Xiaojie Li, et al.
Published: (2020-01-01) -
Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases
by: Nausicaa Clemente, et al.
Published: (2016-01-01)